SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

• J. Cassinello ^[5] ; J. Á. Arranz ^[6] ; J. M. Piulats ^[7] ; A. Sánchez ^[10] ; B. Pérez-Valderrama ^[8] ; B. Mellado ^[9] ; M. Á. Climent ^[1] ; D. Olmos ^[2] ; J. Carles ^[3] ; M. Lázaro ^[4]
  1. [1] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  2. [2] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  3. [3] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  4. [4] Complexo Hospitalario Universitario de Vigo

     Complexo Hospitalario Universitario de Vigo

     Vigo, España

     
  5. [5] Hospital Universitario de Guadalajara

     Hospital Universitario de Guadalajara

     Guadalajara, España

     
  6. [6] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  7. [7] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  8. [8] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  9. [9] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  10. [10] Consorcio Hospitalario Provincial de Castellón, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 57-68
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.